the full WP markdown article
Eli Lilly Crushes Q4 2025 Earnings With Massive Zepbound Boost
Eli Lilly just dropped their Q4 2025 earnings, and the numbers are staggering – revenue way above expectations thanks to Zepbound and Mounjaro. But what does the strong 2026 guidance really mean for investors, and is the GLP-1 boom here to stay? ...
Financial market analysis from 04/02/2026. Market conditions may have changed since publication.
❝
The art is not in making money, but in keeping it.
— Proverb
Author
Steven Soarez passionately shares his financial expertise to help everyone better understand and master investing. Contact us for collaboration opportunities or sponsored article inquiries.
Previous
AMD Stock Drops 9% Post-Earnings: What Really Happened
Next
Sheryl Sandberg Backs AI Workplace Startup Slashwork
Related Articles
Market News
UK’s Criminal Justice Reforms: A Threat to Freedom?
Are the UK's criminal justice reforms a step toward efficiency or tyranny? Discover the chilling changes proposed and what they mean for your rights...
Jul 13, 2025
6 min read
Growth Picks
2026 Small-Cap Biotech Catalysts: Goldman’s Top Picks
As 2025 wraps up, investors are eyeing a blockbuster year for small-cap biotechs. With major Phase 2 data, pivotal trial starts, and potential approvals on the horizon, 2026 could deliver massive value unlocks. But which companies are poised to shine brightest? The catalysts are stacking up...
Dec 28, 2025
6 min read
Market News
MongoDB CEO Transition: Ittycheria Steps Down for Desai
In the fast-paced world of tech, leadership changes can reshape a company's trajectory. As MongoDB's long-time CEO bows out after a stellar run, a fresh face from Cloudflare steps in. But will this pivot fuel the next big leap in database innovation, or test the waters of uncertainty?
Nov 3, 2025
10 min read